What Visus Therapeutics does

Visus Therapeutics is a clinical-stage ophthalmic pharmaceutical company founded in 2017 and headquartered in Seattle, Washington, that developed Yuvezzi, the first and only FDA-approved fixed-dose combination eye drop for presbyopia. Yuvezzi combines carbachol (a cholinergic agonist) and brimonidine tartrate (an alpha-2 adrenergic agonist) in a single prescription formulation, with Phase 3 trials (536 patients) demonstrating superiority over individual components and a duration of effect of up to 10 hours with no serious adverse effects over 12 months. The company also filed BRIMOCHOL PF (NDA accepted June 2025), a related presbyopia asset within the same chemical family.

In December 2024 Visus merged with Tenpoint Therapeutics Ltd., consolidating pipelines targeting presbyopia, cataracts, and geographic atrophy under a combined entity headquartered at 25 Independence Blvd., Suite 100, Warren, NJ; Visus now operates as an affiliate of Tenpoint. Yuvezzi received FDA approval on January 29, 2026, and is planned for U.S. commercial launch in Q2 2026.

Visus/Tenpoint generates revenue (once launched) through prescription pharmaceutical sales distributed via retail and specialty pharmacies, with prescribing driven through an enterprise field sales motion targeting ophthalmologists and optometrists. The company maintains a dedicated eye care professional portal (yuvezziecp.com) to support prescriber engagement. Pre-launch, the company is pre-revenue; cumulative capital raised totals approximately $235 million, including a $85 million Series B led by Janus Henderson with EQT Nexus, Hillhouse, and the British Business Bank, plus a $150 million debt facility from Hercules Capital. Leadership includes co-founder and CEO Ben Bergo, SVP of Business Development and Marketing Jehan Tamboowalla, and CFO Melissa Epperly.

Name

Visus Therapeutics

Legal name

Visus Therapeutics, Inc.

Website

https://visustx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Visus Therapeutics is a clinical-stage ophthalmic pharmaceutical company that developed Yuvezzi, the first FDA-approved fixed-dose combination eye drop for presbyopia. Now an affiliate of Tenpoint Therapeutics following a December 2024 merger, with U.S. commercial launch planned for Q2 2026.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industry

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)

Keywords

• Presbyopia eye drops
• Ophthalmic pharmaceuticals
• Fixed-dose combination
• Prescription therapeutics
• Vision restoration

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Prescription Pharmaceutical Sales: Revenue generated from selling prescription eye drop medications (Yuvezzi) through pharmacies and eye care professionals. Launch planned for Q2 2026 following FDA approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

Visus Therapeutics develops prescription ophthalmic pharmaceutical products for age-related vision conditions, principally presbyopia. Its lead product, Yuvezzi, is the first FDA-approved fixed-dose combination eye drop combining carbachol and brimonidine tartrate, offering up to 10 hours of functional near vision improvement. The company is also developing BRIMOCHOL PF, a presbyopia candidate in the same therapeutic class.

Product overview

Visus Therapeutics, a Seattle-based company that merged with Tenpoint Therapeutics, developed Yuvezzi as its lead product. Yuvezzi is a dual-agent combination eye drop (carbachol and brimonidine tartrate) designed to treat presbyopia, an age-related vision condition affecting near focus. The company previously filed for NDA for BRIMOCHOL PF, which appears to be related to or part of the same product family. Following the merger, Tenpoint now handles commercialization of Yuvezzi after receiving FDA approval in January 2026.

Differentiator

Problem solved

Functional benefit

Brands

• Yuvezzi: Presbyopia eye drop treatment combining carbachol and brimonidine tartrate - the first fixed-dose combination therapy for age-related vision condition affecting approximately 2 billion people globally.

Products and services

• Yuvezzi Yuvezzi is a prescription dual-agent combination eye drop therapy combining carbachol and brimonidine tartrate, indicated for the treatment of presbyopia (age-related loss of near visual acuity) in adults. It is the first and only fixed-dose combination therapy approved by the FDA for presbyopia, providing up to 10 hours of functional near vision improvement.

Quantifiable outcome

• Phase 3 trials demonstrated superiority over individual components with no serious adverse effects over 12-month safety study
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Tenpoint TherapeuticsflagshipStrategic or Co-development PartnerVisus Therapeutics merged with Tenpoint Therapeutics in December 2024 to form a combined company focused on ophthalmic medicines. The merger consolidated pipelines targeting presbyopia, cataracts, and geographic atrophy. Yuvezzi originated from Visus and received FDA approval under the combined entity.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Allergan (AbbVie): Markets Vuity (pilocarpine 1.25%), the first FDA-approved presbyopia eye drop. Direct therapeutic competitor to Yuvezzi and a broad ophthalmology incumbent with deep commercial reach and prescriber relationships.
• Bausch + Lomb: Major ophthalmic company with broad portfolio across prescription pharmaceuticals, surgical devices, and consumer vision care. Comparable as a broad incumbent selling through the same ECP channel and addressing adjacent vision-correction categories.
• Aerie Pharmaceuticals (Alcon): Ophthalmic pharmaceutical company specializing in glaucoma and retinal diseases; acquired by Alcon. Comparable as a specialty ophthalmic pharma peer developing prescription therapies through the same ECP channel.

Direct peers

• Lenz Therapeutics: Clinical-stage ophthalmic company developing aceclidine-based presbyopia eye drops (LNZ100/LNZ101). Directly competes with Yuvezzi in the prescription presbyopia drop category with a similar regulatory and commercial pathway.
• Orasis Pharmaceuticals: Developed Qlosi (pilocarpine 0.4%), an FDA-approved presbyopia eye drop. Directly competes with Yuvezzi in the same ECP prescribing channel and patient population.
• Ocuphire Pharma: Late clinical-stage ophthalmic pharmaceutical company developing therapies for refractive and presbyopia indications. Direct specialty-pharma peer with similar regulatory and commercial pathway targeting ECPs.

Emerging players

• Eyenovia: Ophthalmic pharmaceutical company developing microdose array print platform therapies for presbyopia and myopia. Comparable as an emerging ophthalmic drug-delivery peer targeting similar presbyopia patient population.
• Aldeyra Therapeutics: Clinical-stage ophthalmic company developing reproxalap and other therapies for dry eye and anterior segment conditions. Comparable as an emerging ophthalmic pharmaceutical peer in adjacent therapeutic categories.
• Oyster Point Pharma (Viatris): Ophthalmic pharmaceutical company developing OC-01 (tyrosine derivative) nasal spray for dry eye; acquired by Viatris. Comparable as an emerging prescription ophthalmic pharma peer commercializing through eye care professionals.

Regional players

• Nicox Ophthalmics: European-based ophthalmic pharmaceutical company focused on glaucoma and ocular surface disease. Comparable as a specialty ophthalmic pharma peer with similar development focus and ECP channel, though primarily serving European markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/visus-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Visus Therapeutics